Inventor · disambiguated record
Dirk Scharn
Also filed as: SCHARN DIRK
11 granted patents·10 pending applications·26 citations·filing 2002–2024
84Inventor score
Files withBOEHRINGER INGELHEIM INT10JERINI AG5ZISCHINSKY GUNTHER2GIBSON CHRISTOPH1JPT PEPTIDE TECHNOLOGIES GMBH1
Top patents by PatentIndex Score
21 records- 0180US8071810B2C5a receptor antagonistsSCHNATBAUM KARSTEN·Filed 2006·Granted Dec 6, 2011·11 cites·18 claims
- 0274US8029979B2Method for determining the substrate specificity of an enzymeJPT PEPTIDE TECHNOLOGIES GMBH·Filed 2006·Granted Oct 4, 2011·5 cites·14 claims
- 0372US2025122204A1[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORSBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0470US2024358688A1Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitorsBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0569US8927534B2Compounds for the inhibition of integrins and use thereofZISCHINSKY GUNTHER·Filed 2007·Granted Jan 6, 2015·3 cites·4 claims
- 0667US8309735B2Heterocyclic compounds for the inhibition of integrins and use thereofZISCHINSKY GUNTHER·Filed 2007·Granted Nov 13, 2012·2 cites·74 claims
- 0766US2023374021A1[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORSBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 0863US12064421B2Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitorsBOEHRINGER INGELHEIM INT·Filed 2021·Granted Aug 20, 2024·0 cites·23 claims
- 0963US7727960B2C5a receptor antagonistsJERINI AG·Filed 2004·Granted Jun 1, 2010·4 cites·2 claims
- 1062US11608343B2Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2021·Granted Mar 21, 2023·0 cites·34 claims
- 1161US8410134B28-oxy-quinoline derivatives as bradykinin B2 receptor modulatorsGIBSON CHRISTOPH·Filed 2008·Granted Apr 2, 2013·1 cites·36 claims
- 1250US2011065760A1Compounds for the inhibition of rotamases and use thereofJERINI AG·Filed 2009·Application pending·0 cites
- 1346US11174245B2Benzimidazole compounds and derivatives as EGFR inhibitorsBOEHRINGER INGELHEIM INT·Filed 2019·Granted Nov 16, 2021·0 cites·23 claims
- 1446US2004171097A1Method for determining the substrate specificity of an enzymatic activity and a device thereforFiled 2002·Application pending·0 cites
- 1546US2023126204A1[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORSBOEHRINGER INGELHEIM INT·Filed 2021·Application pending·0 cites
- 1646US2023131720A1[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORSBOEHRINGER INGELHEIM INT·Filed 2021·Application pending·0 cites
- 1743US11261184B2[1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2018·Granted Mar 1, 2022·0 cites·16 claims
- 1839US11213520B2Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2017·Granted Jan 4, 2022·0 cites·14 claims
- 1939US2007054904A1Phenol derivatives and their use as rotamase inhibitorsJERINI AG·Filed 2003·Application pending·0 cites
- 2035US2011003756A1C5a Receptor AntagonistsJERINI AG·Filed 2010·Application pending·0 cites
- 2135US2008161232A1C5a Receptor AntagonistJERINI AG·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dirk Scharn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →